Based on these results, TLR4 was identified as the main driver of HCC development in HepPten- mice and resatorvid as the main candidate therapeutic drug for the prevention of NASH-associated HCC. Here, TLR4 is linked to metabolic dysfunction-associated steatohepatitis.